Abstract
In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.
【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, pandemic, Infection, risk, cardiovascular disease, cardiovascular diseases, outcome, severe acute respiratory syndrome Coronavirus, Prevalence, risk stratification, Features, Patient, respiratory, antithrombotic therapy, Evidence, Antithrombotic, antiplatelet, Cardiovascular events, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, increased risk, scientific evidence, antithrombotic therapies, elevated, question, patients with COVID-19, pro-thrombotic, 【제목키워드】 SARS-CoV-2, Biology, group, working, issue, document, Italian,